Raffaelli B, et al. - Researchers examined how discontinuation of preventive erenumab and galcanezumab treatment affects patients with chronic migraine. Data from 16 patients of the open-label extension study phase for the preventive treatment of chronic migraine with galcanezumab (n = 9) and erenumab (n = 7) in a single headache center were incorporated in this retrospective pooled analysis. Migraine data until week 12 after open-label treatment completion, when patients did not have any pharmacological preventive medication, were compared to study baseline values of the double-blind trial period, and to the last 4 weeks of the open-label extension. Significantly reduced monthly migraine days were reported continuously during the entire 12-week observation period after open-label termination compared to baseline. Monthly migraine days between the 12 weeks after open-label termination and the last 4 weeks of the open-label phase were not significantly different. These findings support monoclonal antibodies targeting the CRGP pathway as therapeutically efficacious in chronic migraine prevention after treatment termination up to 12 weeks.